Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120651 | 1.00 | LMNA (0.36) | LMNAHIF1AEPAS1MEN1CYP3A4 | |
| SCHEMBL10668277 | 0.91 | HIF1A (0.41) | LMNAHIF1AEPAS1CNR1 | |
| SCHEMBL10668275 | 0.91 | HIF1A (0.41) | LMNAHIF1AEPAS1CNR1 | |
| SCHEMBL10526698 | 0.85 | LMNA (0.36) | LMNAHIF1AEPAS1MEN1CYP3A4 | |
| SCHEMBL10526701 | 0.85 | LMNA (0.36) | LMNAHIF1AEPAS1MEN1CYP3A4 | |
| SCHEMBL2120470 | 0.84 | — | — | |
| SCHEMBL2120469 | 0.84 | — | — | |
| SCHEMBL23229756 | 0.77 | ALDH1A1 (0.39) | LMNAHIF1AEPAS1MEN1CYP3A4 | |
| SCHEMBL2004869 | 0.77 | CNR1 (0.39) | LMNAHIF1AEPAS1CNR1 | |
| SCHEMBL109274 | 0.77 | HIF1A (0.38) | LMNAHIF1AEPAS1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2226632-B1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8450070-B2 | Method for screening of cell-protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2226632-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | HSF1, HSP90AB1, HSP90AA1 | LMNA 2696/4885HIF1A 905/4885EPAS1 1225/4885 |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | LMNA 1000/4885HIF1A 2361/4885EPAS1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.